

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-13 (Canceled).

14. (New) A compound of formula



or a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

$-b^1=b^2-C(R^{2a})=b^3-b^4$  represents a bivalent radical of formula

$-CH=CH-C(R^{2a})=CH-CH=$  (b-1);

$-N=CH-C(R^{2a})=CH-CH=$  (b-2);

$-CH=N-C(R^{2a})=CH-CH=$  (b-3);

$-N=CH-C(R^{2a})=N-CH=$  (b-4);

$-N=CH-C(R^{2a})=CH-N=$  (b-5);

$-CH=N-C(R^{2a})=N-CH=$  (b-6); or

$-N=N-C(R^{2a})=CH-CH=$  (b-7);

*q* is 0, 1, 2, 3 or 4;

$R^1$  is hydrogen, aryl, formyl,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxycarbonyl,  $C_{1-6}$ alkyl substituted with formyl,  $C_{1-6}$ alkylcarbonyl, or  $C_{1-6}$ alkyloxycarbonyl;

$R^{2a}$  is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl;  $C_{1-6}$ alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl;  $C_{2-6}$ alkenyl substituted with cyano; or  $C_{2-6}$ alkynyl substituted with cyano;

each  $R^2$  independently is hydroxy, halo,  $C_{1-6}$ alkyl optionally substituted with cyano or  $-C(=O)R^4$ ,  $C_{3-7}$ cycloalkyl,  $C_{2-6}$ alkenyl optionally substituted with one or more halogen atoms or cyano,  $C_{2-6}$ alkynyl optionally substituted with one or more halogen atoms or cyano,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di( $C_{1-6}$ alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio,  $-S(=O)_pR^4$ ,  $-NH-S(=O)_pR^4$ ,  $-C(=O)R^4$ ,  $-NHC(=O)H$ ,  $-C(=O)NHNH_2$ ,  $-NHC(=O)R^4$ ,  $-C(=NH)R^4$  or a radical of formula



wherein each A independently is N, CH or  $CR^4$ ;

B is NH, O, S or  $NR^4$ ;

p is 1 or 2; and

$R^4$  is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is  $C_{4-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl, or  $C_{3-7}$ cycloalkyl, whereby each of said aliphatic groups is optionally substituted with one or two substituents independently selected from

(i)  $C_{3-7}$ cycloalkyl,

(ii) indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy or  $C_{1-6}$ alkylcarbonyl,

(iii) phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings is optionally substituted with one, two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; or

L is  $-X-R^3$  wherein

$R^3$  is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings is optionally substituted with two, three, four or five substituents each independently selected from the substituents defined in  $R^2$ ; and

X is  $-NR^1-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-C(=O)-$ ,  $-CHOH-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{1-6}$ alkyloxy, cyano, nitro, polyhalo $C_{1-6}$ alkyl or polyhalo $C_{1-6}$ alkyloxy.

15. (New) A compound as claimed in claim 14 wherein L is  $-X-R^3$ ,  $-X-$  is  $-O-$  or  $-NH-$  and  $R^3$  is phenyl substituted with two or three substituents each independently selected from chloro, bromo, cyano or methyl.

16. (New) A compound as claimed in claim 14 wherein  $R^{2a}$  is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl,  $C_{1-6}$ alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl.

17. (New) A method of treating a subject suffering from Human Immunodeficiency Virus (HIV) infection, comprising administering a therapeutically effective amount of a compound of claim 14 to said subject.

18. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compound as claimed in claim 14.

19. (New) A process for preparing a pharmaceutical composition as claimed in claim 18 comprising mixing a therapeutically effective amount of said compound with a pharmaceutically acceptable carrier.

20. (New) The combination of a compound as defined in claim 14 and another antiretroviral compound.

21. (New) A combined preparation for simultaneous, separate or sequential use in anti-HIV treatment, comprising a product containing (a) a compound as defined in claim 14, and (b) another antiretroviral compound.

22. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 14, and (b) another antiretroviral compound.